104 related articles for article (PubMed ID: 25489726)
21. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
22. [The diagnostic value of quantitative measurement of a proliferation-inducing ligand mRNA in sputum samples from lung cancer patients].
Sun BL; Zhu L; Ding WF; Jing RR; Chu SP; Wang HM
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Mar; 32(3):182-7. PubMed ID: 19575936
[TBL] [Abstract][Full Text] [Related]
23. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.
Katseli A; Maragos H; Nezos A; Syrigos K; Koutsilieris M
Clin Lung Cancer; 2013 Sep; 14(5):513-20. PubMed ID: 23810363
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633
[TBL] [Abstract][Full Text] [Related]
25. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
26. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Tamura M; Ohta Y
Cancer; 2003 Sep; 98(6):1217-22. PubMed ID: 12973845
[TBL] [Abstract][Full Text] [Related]
27. Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer.
Fu L; Guo W; Liu B; Sun L; Bi Z; Zhu L; Wang X; Liu B; Xie Q; Li K
Biomarkers; 2013 Mar; 18(2):126-35. PubMed ID: 23410046
[TBL] [Abstract][Full Text] [Related]
28. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
29. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
Li M; Zhang Q; Wu L; Jia C; Shi F; Li S; Peng A; Zhang G; Song X; Wang C
Oncol Rep; 2014 Apr; 31(4):1961-7. PubMed ID: 24549225
[TBL] [Abstract][Full Text] [Related]
30. Detection of minimal residual disease in lung cancer.
Chudacek J; Bohanes T; Klein J; Benedikova A; Srovnal J; Szkorupa M; Skalicky P; Skarda J; Hajduch M; Neoral C
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):189-93. PubMed ID: 23558472
[TBL] [Abstract][Full Text] [Related]
31. [Expression and diagnosis value of Fascin in non-small cell lung cancer patients].
Liu YG; Gao XD; Yue WT
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2505-7. PubMed ID: 24300277
[TBL] [Abstract][Full Text] [Related]
32. [The function of the level of serum carcinoembryonic antigen on early recurrence of non-small cell lung cancer].
Zhang ZF; Ma JQ; Sun N; Zhang L
Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(13):817-9. PubMed ID: 15363304
[TBL] [Abstract][Full Text] [Related]
33. Identification of serum proteome components associated with progression of non-small cell lung cancer.
Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
[TBL] [Abstract][Full Text] [Related]
34. Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection?
Schmidt B; Engel E; Carstensen T; Weickmann S; John M; Witt C; Fleischhacker M
Lung Cancer; 2005 Apr; 48(1):145-7. PubMed ID: 15777983
[TBL] [Abstract][Full Text] [Related]
35. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
[TBL] [Abstract][Full Text] [Related]
36. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
37. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
38. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
39. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
[TBL] [Abstract][Full Text] [Related]
40. Cytokeratin fragment 19 (CYFRA 21-1) as a tumor marker in non-small cell lung cancer.
Huang MS; Jong SB; Lin MS; Chong IW; Tsai MS; Lin HC; Hwang JJ
Kaohsiung J Med Sci; 1996 Feb; 12(2):62-8. PubMed ID: 8709175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
